US FDA approves Janssen Pharma's Carvykti to treat relapsed or refractory multiple myeloma

Press/Media

Period	2 Mar 2022

Media coverage

Title	US FDA approves Janssen Pharma's Carvykti to treat relapsed or refractory multiple myeloma
Media name/outlet	PharmaBiz
Country/Territory	India
Date	2/03/22
URL	www.pharmabiz.com/NewsDetails.aspx?aid=146141&sid=2
Persons	Sundar Jagannath